Erleva 150 mg Tablet
  1. Home
  2. Pharma Products
  3. Glenmark Pharmaceuticals Ltd
  4. Erleva 150 mg Tablet

Erleva 150 mg Tablet

Erleva 150 mg Tablet contains erlotinib 150 mg and is an oral targeted anticancer medicine used mainly for non-small cell lung cancer and pancreatic cancer. It is taken on an empty stomach, generally at least 1 hour before or 2 hours after food, as prescribed by the treating doctor. Erlotinib blocks epidermal growth factor receptor (EGFR) signaling, which can help slow the growth of certain cancer cells.

BUY NOW

Category

Erleva belongs to the tyrosine kinase inhibitor class and is used in appropriate treatment regimens for specific types of advanced or metastatic non-small cell lung cancer and pancreatic cancer. By inhibiting EGFR signaling, erlotinib interferes with pathways involved in the growth and multiplication of susceptible cancer cells. The 150 mg strength is taken orally according to the oncologist’s prescribed schedule, with treatment duration based on disease response and clinical assessment. Common treatment-related effects include rash, diarrhea, nausea, fatigue, dry skin, and appetite changes, while liver function may require monitoring during therapy.

Technical Specification

Specification Details
Active Ingredient Erlotinib
Strength 150 mg
Dosage Form Tablet
Route of Administration Oral
Recommended Strength 150 mg once daily
Marketer Glenmark Pharmaceuticals Ltd

Product Also Known As

Erleva 150mg Tablet, Erleva 150 mg Tablet, Erlotinib 150mg Tablet, Erlotinib 150 mg Tablet, Erlotinib Tablets 150mg, Erlotinib EGFR Inhibitor Tablet